Michael A. Carson has recently been appointed as president and CEO of Centene Corporation’s Medicare business, Wellcare.
Carson, who succeeds Richard Fisher, will now be responsible for Medicare business performance, strategy and the growth of Wellcare.
Before serving nearly three decades in the healthcare industry, Carson began his career in the United States Air Force, where he served for almost a decade.
He has since developed an array of leadership, operational and industry skills in both the payer and provider space with a focus on serving Medicare and dual-eligible populations.
Carson previously held the positions of CEO at CareAbout, a value-based primary and multi-specialty care startup, as well as at Bright Health Plan and Harvard Pilgrim Health Care.
Additionally, he led the rebuilding of Medicare ventures at Amerigroup and Anthem, while also serving leadership positions at ConcertoHealth and various Blue Cross Blue Shield plans.
In a press release, Carson shared his excitement to support Wellcare’s mission to transform the health of the communities it serves.
"I look forward to helping guide the Medicare business to realize its full potential, driving further innovation and growth as we collaborate with our Medicaid and Marketplace businesses and key provider and member services partners," Carson said.
Wellcare health plans provide government-sponsored healthcare programs nationwide, with some states exclusively offering Prescription Drug Plans (PDP), while the majority offer both PDP and Medicare Advantage (MA) Plans.
Centene has expanded its Medicare presence in recent years, offering various MA products across 37 states. To enhance consumer’s healthcare experience, Centene invests in service initiatives for both members and brokers, providing affordable options for its Medicare beneficiaries.
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen